Lily Chu, MD, MSHS, is board certified in both internal medicine and geriatric medicine.
As per LinkedIn bio:
- Geriatric Medicine Fellowship, University of California, Los Angeles
- MSHS, Public Health, University of California, Los Angeles
- Internal Medicine Residency, University of Rochester
- MD, University of Washington
- BS, Biology, University of Washington
Boards and Committees
- Community Advisory Board Member at Stanford University Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome Initiative
- Co-Vice president of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
- Panel member of the 2015 Institute of Medicine report: Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness
April 2013 FDA Workshop Survey
- Preliminary Results – April 2013 FDA Workshop Survey, By Lily Chu, Leonard Jason, Madison Sunnquist, Suzanna So
Open Letter to The Lancet
Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Chu, along with 41 colleagues in the ME/CFS field, signed the second letter.
- 10 February 2016, An open letter to The Lancet, again - Virology blog
- 2016 - "Ultimately the best way to prevent suicide in ME/CFS will be to find effective disease-modifying treatments or cures for it."
- 2017, Article commentary - Differences of opinion on systemic exercise intolerance disease are not ‘mistakes’: a rejoinder to Jason Sunnquist, Gleason and Fox
- May 2016, Suicide and ME/CFS -- Lily Chu, MD, MSHS
- 2012, "Exercise and chronic fatigue syndrome: maximize function, minimize post-exertional malaise," Letter to the Editor, European Journal of Clinical Investigation
- 2017, Cytokine signature associated with disease severity in chronic fatigue syndrome patients (FULL TEXT)
- 2017, Patients diagnosed with Myalgic encephalomyelitis/chronic fatigue syndrome also fit systemic exertion intolerance disease criteria
Abstract - Background: Myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) remains undiagnosed in up to 91% of patients. Recently, the United States-based Institute of Medicine (IOM) developed new diagnostic criteria, naming it systemic exertion intolerance disease (SEID). Purpose: We examined how subjects fit SEID criteria and existing ME/CFS case definitions early in their illness. Methods: A total of 131 subjects fitting 1994 Fukuda CFS criteria at the time of study recruitment completed a survey of symptoms they experienced during their first 6 months of illness. Symptoms were drawn from SEID and existing criteria (1994 Fukuda, 2003 Canadian Consensus Criteria (CCC), and 2011 Myalgic Encephalomyelitis-International Consensus Criteria (ME-ICC)). We calculated and compared the number/percentage of subjects fitting single or combinations of case definitions and the number/percentage of subjects with SEID experiencing orthostatic intolerance (OI) and/or cognitive impairment. Results: At 6 months of illness, SEID criteria identified 72% of all subjects, similar to when Fukuda criteria (79%) or the CCC (71%) were used, whereas the ME-ICC selected for a significantly lower percentage (61%, p < .001). When severity/frequency thresholds were added to the Fukuda criteria, CCC and ME-ICC, the percentage of these subjects also fitting SEID criteria increased to 93%, 97%, and 95%. Eighty-seven percent of SEID subjects endorsed cognitive impairment and 92%, OI; 79% experienced both symptoms. Conclusions: SEID criteria categorize a similar percentage of subjects as Fukuda criteria early in the course of ME/CFS and contain the majority of subjects identified using other criteria while requiring fewer symptoms. The advantage of SEID may be in its ease of use.
Talks and Interviews
Questions to NIH during Advocacy Call
- 2 Nov 2016, NIH ME/CFS Advocacy Call with Dr. Walter Koroshetz, Dr. Vicky Whittemore, Dr. Joseph Breen, and Dr. Avindra Nath - (Recorded call and Transcript) - During the question and answer session, Dr Chu asked if the ME/CFS interest group seminars would be online and open to extramural investigators but was told by Dr. Avindra Nath that the seminars were set up to be one-on-one interactions.
- CFSAC Public Testimony December 2014
- Written Testimony for June 2012 meeting
- Written Testimony for Nov 2011 meeting
- Written Testimony for May 2011 meeting
- Written Testimony for October 2009 meeting
- Chu, Lily; Valencia, Ian J.; Montoya, Jose G. (2017), "Differences of opinion on systemic exercise intolerance disease are not ‘mistakes’: a rejoinder to Jason Sunnquist, Gleason and Fox", Fatigue: Biomedicine, Health & Behavior, doi:10.1080/21641846.2017.1362750
- Chu, L.; Friedberg, F.; Friedman, K.J.; Littrell, N.; Stevens, S.; Vallings (2012), "Exercise and chronic fatigue syndrome: maximize function, minimize post-exertional malaise", European Journal of Clinical Investigation, 42: 1362, doi:10.1111/j.1365-2362.2012.02723.x
- Montoya, Jose G.; Holmes, Tyson H.; Anderson, Jill N.; Maecker, Holden T.; Rosenberg-Hasson, Yael; Valencia, Ian J.; Chu, Lily; Younger, Jarred W.; Tato, Cristina M.; Davis, Mark M. (2017), "Cytokine signature associated with disease severity in chronic fatigue syndrome patients", Proceedings of the National Academy of Sciences of the United States of America, 114 (34): E7150-E7158, doi:10.1073/pnas.1710519114
- Chu, Lily; Norris, Jane; Valencia, Ian J.; Montoya, Jose G. (2017), "Patients diagnosed with Myalgic encephalomyelitis/chronic fatigue syndrome also fit systemic exertion intolerance disease criteria", Fatigue: Biomedicine, Health & Behavior, 5, doi:10.1080/21641846.2017.1299079